BIO 1050

Drug Profile

BIO 1050

Latest Information Update: 07 Mar 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biogen
  • Developer Biogen; Merck & Co
  • Class Antiasthmatics; Ischaemic heart disorder therapies
  • Mechanism of Action Integrin alpha4beta1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Angina pectoris; Asthma; Stroke

Most Recent Events

  • 12 Oct 1999 No-Development-Reported for Angina pectoris in USA (Unknown route)
  • 12 Oct 1999 No-Development-Reported for Asthma in USA (Unknown route)
  • 12 Oct 1999 No-Development-Reported for Stroke in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top